To characterize the prevalence of and contributing factors to adult obesity in the most common recurrent copy-number variation (CNV), 22q11.2 deletion, given that other rare CNVs are known to have ...

Purpose: To determine the incidence of 22q11.2 microdeletions in the adult survivors of correction of tetralogy of Fallot who have familial congenital heart disease. Methods: Patients who had survived ...

A recent study led by UC Davis Health researchers provides new insights into the molecular changes linked to the rare genetic condition 22q11.2 deletion syndrome, or 22q. It found unique biomarkers ...

The brain activity patterns during sleep shed light on the neurobiology behind a genetic condition called 22q11.2 Deletion Syndrome (22q11.2DS) and could be used as a biomarker to detect the onset of ...

Dublin, June 25, 2025 (GLOBE NEWSWIRE) -- The "22q11.2 Deletion Syndrome Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets.com's ...

The efficacy and safety of Zygel is being evaluated in the INSPIRE study. The Food and Drug Administration (FDA) has granted Orphan Drug designation to Zygel™ (cannabidiol gel; Zynerba Pharmaceuticals ...

A new study published in Science Advances sheds light on how changes in brain connections before and after puberty might explain why some children with a rare genetic condition called 22q11.2 deletion ...

Nobias Therapeutics, a clinical-stage company developing novel small-molecule therapeutics for rare diseases, today announced that it has secured preliminary alignment with the U.S. Food and Drug ...

Zynerba Pharmaceuticals, Inc. ZYNE presented positive long-term 38-week data from the phase 2 INSPIRE trial with Zygel in children and adolescents with 22q11.2 deletion syndrome. The data were ...

Schizophrenia may be related to the deletion syndrome. However, not everyone who has the syndrome necessarily develops psychotic symptoms. What triggers the illness? Researchers (UNIGE) have provided ...